vaccineSwiss vaccine developer Limma Tech get CARB-X grantLatest NewsSwiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Read more 28 February 2024 https://european-biotechnology.com/wp-content/uploads/2024/04/Limmatech.jpg 430 945 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2024-02-28 16:00:452024-06-13 14:33:29Swiss vaccine developer Limma Tech get CARB-X grant